RxDoctor Payments Data

Eric Wu, MD

Ophthalmology · Batavia, NYNPI 1205027935

Payments from drug & device makers

$1,685in general payments, 2019–2025

Across 52 payments — averaging $32.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$424
  • Aerie Pharmaceuticals, Inc.$281
  • Novartis$246
  • Alcon$169
  • Tactile Systems Technology Inc$150
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$126
  • plus $288 from 7 others

What the payments were for

  • Food & beverage$1,685100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,685 in reported general payments places this provider in the 55th percentile of 1,587 ophthalmology providers in New York.

See all ophthalmology providers in New York

Medicare billing

Part B allowed, 2024
$182,676
Medicare patients
546
Services billed
1,503

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine44$73,603
LumiganBimatoprost102$45,422
RocklatanNetarsudil Mesylat/Latanoprost65$29,949
Cyclosporine50$28,023
XiidraLifitegrast14$25,869
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol142$19,556
Travoprost47$12,793
Latanoprost1,026$11,188
Alphagan PBrimonidine Tartrate18$7,422
Brimonidine Tartrate88$7,293
RhopressaNetarsudil Mesylate11$6,986
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat288$5,609
Prednisolone Acetate169$5,389
SimbrinzaBrinzolamide/Brimonidine Tart12$2,403
Bimatoprost12$2,080

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Alphagan P$424$126,447164 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$281$36,93576 claims
Bausch & Lomb Americas Inc.Xiidra$33$25,86914 claims
AlconSimbrinza$169$2,40312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,587 ophthalmology providers in New York.

Other ophthalmology in Batavia

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →